Dear GGMC Community,

With a heavy heart, I must share a critical update. The Global Genomic Medicine Collaborative, built on your dedication to advancing multi-omic research and patient care, faces a serious financial challenge. Despite significant cost reductions and relentless efforts to secure new funding – as highlighted in my recent article on the challenges facing international genomic initiatives – we have reached a precarious point with only ten weeks of operating funds remaining. We are at a crossroads.

As we urgently explore sustainable revenue streams, and to more deeply understand the value of GGMC to our members, we encourage all G2MC and IHCC members to complete the brief survey recently shared. Additionally, if you or someone in your network has insights or ideas on funding solutions, let’s connect.

Towards that end, this newsletter highlights the recent launch of our “Cohorts to Clinics (C2C)” program, designed to bridge the gap between genomic research and clinical application by coordinating the strengths of IHCC and G2MC. As we continue to seek support for the continuation of GGMC, we still encourage your active engagement in this strategic new program. To support the C2C initiative, we have opened the GGMC Membership Portal for all current and future members. We will gather details about the knowledge and expertise of our membership so we can form and support C2C project teams and communities.

Under our reduced budget, we are supporting continued activities around the IHCC Cohort Atlas, the G2MC Epilepsy Clinical Forum, and our monthly GGMC Educational Webinar Series. Lastly, in this newsletter, we are pleased to share the GGMC 2024 Annual Report, highlighting the significant achievements made possible by our collective efforts.

We encourage all to create a GGMC online account and contribute to the programs highlighted there. Thank you for your continued commitment and your enduring belief in the power of global collaboration to advance genomic medicine. Together, we must navigate these challenges with urgency and determination to ensure that GGMC can continue to shape the future of genomic medicine.